<scp>METTL3</scp> ‐mediated <scp>m6A</scp> modification of lnc <scp>RNA RHPN1‐AS1</scp> enhances cisplatin resistance in ovarian cancer by activating <scp>PI3K</scp> / <scp>AKT</scp> pathway-Reference-Cited by-同舟云学术

METTL3 ‐mediated m6A modification of lnc RNA RHPN1‐AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K / AKT pathway

Published:2022-11-06 Issue:12 Volume:36 Page:
ISSN:0887-8013
Container-title:Journal of Clinical Laboratory Analysis
language:en
Short-container-title:Clinical Laboratory Analysis

Author:

Cui Shoubin¹^ORCID

Affiliation:

1. Department of Gynaecology and Obstetrics Yantai Affiliated Hospital of Binzhou Medical University Yantai Shandong China

Publisher

Wiley

Subject

Microbiology (medical),Biochemistry (medical),Medical Laboratory Technology,Clinical Biochemistry,Public Health, Environmental and Occupational Health,Hematology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcla.24761

Reference59 articles.

1. Evaluation of microparticulate ovarian cancer vaccine via transdermal route of delivery

2. Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancer

3. Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer

4. Acquired chemotherapy resistance in ovarian cancer

5. Exploring long non-coding RNAs through sequencing

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging role of m6A modification in ovarian cancer: progression, drug resistance, and therapeutic prospects;Frontiers in Oncology;2024-03-13

2. Non-coding RNA-Mediated N6-Methyladenosine (m6A) deposition: A pivotal regulator of cancer, impacting key signaling pathways in carcinogenesis and therapy response;Non-coding RNA Research;2024-03

3. METTL3/MALAT1/ELAVL1 Axis Promotes Tumor Growth in Ovarian Cancer;OncoTargets and Therapy;2024-02

4. Research Advances in the Roles of N6-Methyladenosine Modification in Ovarian Cancer;Cancer Control;2024-01

5. New insights into the interaction between m6A modification and lncRNA in cancer drug resistance;Cell Proliferation;2023-11-14